Meeting
2016 ASCO Annual Meeting
A phase I study of chemo-radiotherapy with plerixafor for newly diagnosed glioblastoma (GB).
Authors
Reena Parada Thomas
Stanford University Hospital, Stanford, CA
Reena Parada Thomas , Seema Nagpal , Michael Iv , Scott G. Soltys , Zachary Corbin , Linda Wei Xu , Cathy Kahn Recht , Sophie Bertrand , Vani Jain , Brenda Acevedo , Martin Brown , Lawrence David Recht
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01977677
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2068)
DOI
10.1200/JCO.2016.34.15_suppl.2068
Abstract #
2068
Poster Bd #
255
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Phase I/randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study.
First Author: Nadia N. Laack
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers
Poster
2017 ASCO Annual Meeting
Association of SDF1 inhibition with local control and relative cerebral blood volume of glioblastoma.
First Author: Reena Parada Thomas
Poster
2013 ASCO Annual Meeting
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
First Author: Lawrence Kleinberg